Walayat Saqib, Johannes Andrew J, Benson Mark, Nelsen Eric, Akhter Ahmed, Kennedy Gregory, Soni Anurag, Reichelderfer Mark, Pfau Patrick, Gopal Deepak
Department of Gastroenterology, University of Wisconsin, Madison, WI 53705, United States.
Department of Gastroenterology and Hepatology, University of Wisconsin, Madison, WI 53705, United States.
World J Gastrointest Endosc. 2023 Apr 16;15(4):309-318. doi: 10.4253/wjge.v15.i4.309.
Endoscopic placement of a self-expandable metal stent (SEMS) is a minimally invasive treatment for use in malignant and benign colonic obstruction. However, their widespread use is still limited with a nationwide analysis showing only 5.4% of patients with colon obstruction undergoing stent placement. This underutilization could be due to perceived increase risk of complications with stent placement.
To review long- and short-term clinical success of SEMS use for colonic obstruction at our center.
We retrospectively reviewed all the patients who underwent colonic SEMS placement over a eighteen year period (August 2004 through August 2022) at our academic center. Demographics including age, gender, indication (malignant and benign), technical success, clinical success, complications (perforation, stent migration), mortality, and outcomes were recorded.
Sixty three patients underwent colon SEMS over an 18-year period. Fifty-five cases were for malignant indications, 8 were for benign conditions. The benign strictures included diverticular disease stricturing ( = 4), fistula closure ( = 2), extrinsic fibroid compression ( = 1), and ischemic stricture ( = 1). Forty-three of the malignant cases were due to intrinsic obstruction from primary or recurrent colon cancer; 12 were from extrinsic compression. Fifty-four strictures occurred on the left side, 3 occurred on the right and the rest in transverse colon. The total malignant case ( = 55) procedural success rate was 95% 100% for benign cases ( = 1.0, NS). Overall complication rate was significantly higher for benign group: Four complications were observed in the malignant group (stent migration, restenosis) 2 of 8 (25%) for benign obstruction (1-perforation, 1-stent migration) ( = 0.02). When stratifying complications of perforation and stent migration there was no significant difference between the two groups ( = 0.14, NS).
Colon SEMS remains a worthwhile option for colonic obstruction related to malignancy and has a high procedural and clinical success rate. Benign indications for SEMS placement appear to have similar success to malignant. While there appears to be a higher overall complication rate in benign cases, our study is limited by sample size. When evaluating for perforation alone there does not appear to be any significant difference between the two groups. SEMS placement may be a practical option for indications other that malignant obstruction. Interventional endoscopists should be aware and discuss the risk for complications in setting of benign conditions. Indications in these cases should be discussed in a multi-disciplinary fashion with colorectal surgery.
自膨式金属支架(SEMS)的内镜置入是治疗恶性和良性结肠梗阻的一种微创方法。然而,其广泛应用仍然有限,一项全国性分析显示,只有5.4%的结肠梗阻患者接受了支架置入。这种未充分利用可能是由于人们认为支架置入的并发症风险增加。
回顾我院中心使用SEMS治疗结肠梗阻的短期和长期临床疗效。
我们回顾性分析了在我院学术中心18年期间(2004年8月至2022年8月)接受结肠SEMS置入的所有患者。记录患者的人口统计学信息,包括年龄、性别、适应证(恶性和良性)、技术成功率、临床成功率、并发症(穿孔、支架移位)、死亡率和预后情况。
18年间63例患者接受了结肠SEMS置入。55例为恶性适应证,8例为良性疾病。良性狭窄包括憩室病狭窄(4例)、瘘管闭合(2例)、外在肌瘤压迫(1例)和缺血性狭窄(1例)。55例恶性病例中,43例是由原发性或复发性结肠癌引起的内在梗阻,12例是由外在压迫引起的。54例狭窄发生在左侧,3例发生在右侧,其余在横结肠。恶性病例的总手术成功率为95%,良性病例为100%(P = 1.0,无显著性差异)。良性组的总体并发症发生率显著更高:恶性组观察到4例并发症(支架移位、再狭窄),良性梗阻组8例中有2例(25%)(1例穿孔,1例支架移位)(P = 0.02)。当对穿孔和支架移位并发症进行分层时,两组之间无显著差异(P = 0.14,无显著性差异)。
结肠SEMS仍然是治疗与恶性肿瘤相关的结肠梗阻的一个有价值的选择,具有较高的手术成功率和临床成功率。SEMS置入的良性适应证似乎与恶性适应证有相似的成功率。虽然良性病例的总体并发症发生率似乎较高,但我们的研究受样本量限制。单独评估穿孔时,两组之间似乎没有任何显著差异。对于恶性梗阻以外的适应证,SEMS置入可能是一种可行的选择。介入内镜医师应意识到并讨论良性疾病情况下的并发症风险。这些病例的适应证应与结直肠外科进行多学科讨论。